Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2012 | short review

Update on lung cancer from the annual meeting of the American Society of Clinical Oncology 2012

verfasst von: Sacha I. Rothschild, MD, PhD, Oliver Gautschi, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago, Illinois (USA) from June 1–5, 2012. In the lung cancer track, several hundreds of abstracts were presented. The following article will give an overview on some interesting and relevant abstracts. Beside new drugs, the role of biomarker, and maintenance therapy, we will also discuss issues on early-stage disease.
Vorheriger Artikel The individualization of treatment based on molecular markers
Nächster Artikel Primary angiosarcoma of the breast with a poor prognosis primarily masquerading as hemangioma
Literatur
1.
Senan S, Verstegen NE, Palma D, Rodrigues G, Lagerwaard FJ, van der Elst A, et al. Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): outcomes of a propensity score-matched analysis. J Clin Oncol. 2012;30 (Suppl; abstract 7009).
2.
Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008 Jul 20;26(21):3552–9.PubMedCrossRef
3.
Shepherd FA, Bourredjem A, Brambilla E, Domerg C, Douillard J-Y, Filipits M, et al. Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): a LACE-bio study. J Clin Oncol. 2012;30 (Suppl; abstract 7007).
4.
Yamamoto S, Tsjujino K, Ando M, Kawaguchi T, Kubo A, Isa S, et al. Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature. J Clin Oncol. 2012;30 (Suppl; abstract 7000).
5.
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. (Clinical Trial, Phase III, Randomized Controlled Trial, Research Support, Non-U.S. Gov’t) 1999 Sep;17(9):2692–9.
6.
Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. (Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov’t) 2004 Oct;46(1):87–98.PubMedCrossRef
7.
Huber RM, Engel-Riedel W, Kollmeier J, Andreas S, Staar S, Klautke G, et al. GILT study: oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): final results of a phase (ph) III study. J Clin Oncol. 2012;30 (Suppl; abstract 7001).
8.
Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. (Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov’t) 2012 Mar;13(3):247–55.PubMedCrossRef
9.
Paz-Ares L, De Marinis F, Dediu M, Thomas M, Pujol J-L, Bidoli P, et al. PARAMOUNT: final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30 (Suppl; abstract LBA7507).
10.
Yang JC-H, Schuler MH, Yamamoto N, O’Byrne KJ, Hirsh V, Mok T, et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol. 2012;30 (Suppl; abstract LBA7500).
11.
Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. (Clinical Trial, Phase II Research Support, Non-U.S. Gov’t) 2012 May;13(5):539–48.PubMedCrossRef
12.
Garassino MC, Martelli O, Bettini A, Floriani I, Copreni E, Lauricella C, et al. TAILOR: a phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol. 2012;30 (Suppl; abstract LBA7501).
13.
Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. (Clinical Trial, Phase III, Comparative Study, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov’t) 2012 Mar;13(3):300–8.PubMedCrossRef
14.
Kim ES, Neubauer MA, Cohn AL, Schwartzberg LS, Garbo LE, Caton JR, et al. SELECT: randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy. J Clin Oncol. 2012;30 (Suppl; abstract 7502).
15.
Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012 Jan;13(1):33–42.PubMedCrossRef
16.
Lilenbaum R, Zukin M, Pereira JR, Barrios CH, De Albuquerque Ribeiro R, Augusto de Mendonça Beato C, et al. A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. J Clin Oncol. 2012;30 (Suppl; abstract 7506).
17.
Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. (Meta-Analysis Review) 2005 Jan 17;92(1):131–9.PubMedCrossRef
18.
Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. (Clinical Trial, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.) 2005 Jun 23;352(25):2589–97.PubMedCrossRef
19.
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. (Clinical Trial, Phase III, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov’t) 2005 Sep 1;23(25):5900–9.PubMedCrossRef
20.
Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. (Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.) 2005 Jan;2(1):e17.PubMedCrossRef
21.
Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007 Mar 1;13(5):1576–83.PubMedCrossRef
22.
Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007 Aug;6(8):2209–19.PubMedCrossRef
23.
Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios CH, et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30 (Suppl; abstract 7503).
24.
Brahmer JR, Horn L, Antonia S, Spigel DR, Gandhi L, Sequist LV, et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol. 2012;30 (Suppl; abstract 7509).
25.
Hellerstedt BA, Edelman G, Vogelzang NJ, Kluger HM, Yasenchak CA, Shen X, et al. Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30 (Suppl; abstract 7514).
26.
Kim D-W, Ahn M-J, Shi Y, De Pas TM, Yang P-C, Riely GJ, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30 (Suppl; abstract 7533).
27.
Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010 Nov 15;16(22):5581–90.PubMedCrossRef
28.
Salido M, Pijuan L, Martinez-Aviles L, Galvan AB, Canadas I, Rovira A, et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol. 2011 Jan;6(1):21–7.PubMedCrossRef
29.
Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472–82.PubMedCrossRef
30.
Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Schulte N, Maxson D, et al. Native and rearranged ALK copy number and rearranged ALK cell count in NSCLC: implications for ALK inhibitor therapy. J Clin Oncol. 2012;30 (Suppl; abstract 7534).
31.
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. (Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t) 2012 Mar 10;30(8):863–70.PubMedCrossRef
32.
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. (Research Support, Non-U.S. Gov’t) 2012 Mar;18(3):378–81.PubMedCrossRef
33.
McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. (Comparative Study, Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t) 2008 May 1;68(9):3389–95.PubMedCrossRef
34.
Shaw AT, Camidge DR, Engelman JA, Solomon BJ, Kwak EL, Clark JW, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol. 2012;30 (Suppl; abstract 7508).
35.
Suehara Y, Arcila ME, Dela Cruz Drilon AE, Ito T, Wang L, Hasanovic A, et al. KIF5B-RET: discovery of a novel fusion oncogene in lung adenocarcinomas by a systematic screen for tyrosine kinase fusions and identification of patients for a RET targeted therapy trial. J Clin Oncol. 2012;30 (Suppl; abstract 7578).
Metadaten
Titel
Update on lung cancer from the annual meeting of the American Society of Clinical Oncology 2012
verfasst von
Sacha I. Rothschild, MD, PhD
Oliver Gautschi, MD
Publikationsdatum
01.12.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0050-z

Weitere Artikel der Ausgabe 4/2012

Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors

  • short review

Late lung metastasis of primary endometrial cancer

  • case report

New developments in gastrointestinal cancer—ASCO 2012

  • short review

Significant heterogeneity between centers during early evaluation of the first Turkish multi-centric study in the treatment of childhood acute lymphoblastic leukemia

  • short review

The individualization of treatment based on molecular markers

  • editorial

A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report

  • case report